Drugs Made In America Acquisition II Corp. (DMII)
NASDAQ: DMII · Real-Time Price · USD
10.07
+0.01 (0.09%)
Jun 2, 2026, 4:00 PM EDT - Market closed
Company Description
Drugs Made In America Acquisition II Corp. does not have significant operations.
The company focuses on effecting a merger, share exchange, asset acquisition, share purchase, recapitalization, reorganization, or other similar business combination with one or more businesses.
It intends to source and evaluate companies focused on the pharmaceutical sector. Drugs Made In America Acquisition II Corp. was incorporated in 2024 and is based in New York, New York.
Drugs Made In America Acquisition II Corp.
| Country | United States |
| Founded | 2024 |
| IPO Date | Sep 25, 2025 |
| Industry | Shell Companies |
| Sector | Financials |
| CEO | Roger Bendelac |
Contact Details
Address: 420 Lexington Avenue, Suite 1402 New York, New York 10170 United States | |
| Phone | 917 982 4565 |
Stock Details
| Ticker Symbol | DMII |
| Exchange | NASDAQ |
| Fiscal Year | January - December |
| Reporting Currency | USD |
| IPO Price | $10.00 |
| CIK Code | 2040475 |
| CUSIP Number | G2851K104 |
| ISIN Number | KYG2851K1040 |
| SIC Code | 6770 |
Key Executives
| Name | Position |
|---|---|
| Roger Bendelac | Chief Executive Officer |
| Saleem Elmasri CPA | Chief Financial Officer and Principal Accounting Officer |
Latest SEC Filings
| Date | Type | Title |
|---|---|---|
| May 14, 2026 | 10-Q | Quarterly Report |
| Apr 28, 2026 | 8-K | Current Report |
| Apr 15, 2026 | 10-K | Annual Report |
| Apr 3, 2026 | 8-K | Current Report |
| Apr 1, 2026 | NT 10-K | Notification of inability to timely file Form 10-K 405, 10-K, 10-KSB 405, 10-KSB, 10-KT, or 10-KT405 |
| Mar 17, 2026 | 8-K | Current Report |
| Mar 6, 2026 | 8-K | Current Report |
| Mar 6, 2026 | 8-K | Current Report |
| Nov 18, 2025 | 10-Q | Quarterly Report |
| Nov 18, 2025 | 8-K | Current Report |